These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 22005066

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2001 Sep 21; 50(37):800-4. PubMed ID: 11785571
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L, de Andrade C, Dalla Costa T.
    Int J Antimicrob Agents; 2011 Oct 21; 38(4):307-13. PubMed ID: 21802907
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT, Blondeau JM.
    J Chemother; 2005 Oct 21; 17(5):484-92. PubMed ID: 16323436
    [Abstract] [Full Text] [Related]

  • 30. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar 21; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Pneumococcus and quinolone resistance].
    Bello S, Torres A.
    Arch Bronconeumol; 2003 Mar 21; 39(3):97-100. PubMed ID: 12622966
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M, Giménez MJ, Vicente D, Aguilar L, Pérez-Trallero E.
    Int J Antimicrob Agents; 2005 Feb 21; 25(2):163-7. PubMed ID: 15664487
    [Abstract] [Full Text] [Related]

  • 35. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR, Burgess DS.
    Pharmacotherapy; 2005 Sep 21; 25(9):1161-7. PubMed ID: 16164390
    [Abstract] [Full Text] [Related]

  • 36. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN, Adam HJ, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2006 Sep 21; 28(3):266-9. PubMed ID: 16904294
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
    Johnson AP, Speller DC, Warner M, Domingue G.
    J Antimicrob Chemother; 1996 Nov 21; 38(5):907-8. PubMed ID: 8961064
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
    Hu BS, Fung CP, Liu PY, Lau YJ, Shi ZY, Lin YH.
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct 21; 60(4):191-4. PubMed ID: 9439047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.